Companies · Pharmaceuticals

EpiVario Inc.

PHILADELPHIA · Pharmaceuticals

Diligence memoA one-page analyst read on EpiVario Inc. — recommendation, valuation, rhythm, risks.
$1.1M
Total raised · real
4
Rounds
0.9×
Latest step-up
Top 81%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Mon Jan 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

EpiVario Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.29× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.5 yr ago; this sector typically re-raises about every 13 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

EpiVario Inc. is one of 1613 Pharmaceuticals companies tracked from PHILADELPHIA. By capital raised it ranks in the long tail (ahead of 20% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2024-01-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2018-09-12 Raised $205K (real) Modeled valuation $9.7M (est)Pre-Seed2018Pre-Seed · 2018-09-12 Raised $540K (real) Modeled valuation $26M (est)Pre-Seed2018Pre-Seed · 2018-09-12 Raised $446K (real) Modeled valuation $21M (est)Pre-Seed2018Pre-Seed · 2018-09-12 Raised $600K (real) Modeled valuation $28M (est)Pre-Seed2018Pre-Seed · 2021-07-30 Raised $233K (real) Modeled valuation $5.9M (est)Pre-Seed2021Pre-Seed · 2022-08-26 Raised $135K (real) Modeled valuation $1.8M (est)Pre-Seed2022Pre-Seed · 2024-01-08 Raised $125K (real) Modeled valuation $750K (est)Pre-Seed2024+$540K+$446K+$600K+$233K+$135K+$125KCumulative $2.3M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$205K · 2018
Pre-Seed extension$540K · 2018
Pre-Seed extension$446K · 2018
Pre-Seed extension$600K · 2018
Pre-Seed extension$233K · 2021
Pre-Seed extension$135K · 2022
Pre-Seed extension$125K · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$750K
Base estimate est.
$70K
Conservative case
$2.9M
Upside case
$694K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $9.7M · 2018-09-122018Pre-Seed · modeled $25.5M · 2018-09-12Pre-Seed · modeled $21.1M · 2018-09-12Pre-Seed · modeled $28.4M · 2018-09-12Pre-Seed · modeled $5.9M · 2021-07-30Pre-Seed · modeled $1.8M · 2022-08-26Pre-Seed · modeled $750K · 2024-01-082024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
2.5 yr
Elapsed time used
2.5 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$205K/yr
Capital velocity
7.8 yr
On record since
2018
First round
7
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$1.1M
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.3× of median
This company$125K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$750K
Sector median$76.1M

Raised more than 20% of sector peers (real $). Modeled value above 2% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #34 of 38.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Eleison Pharmaceuticals Inc · Pre-Seed Raised $980K · modeled $15.9M (est)Telomir Pharmaceuticals, Inc. · Pre-Seed Raised $1.0M · modeled $9.7M (est)Drusolv Therapeutics, Inc. · Pre-Seed Raised $500K · modeled $8.5M (est)TF Tech Ventures, Inc. · Pre-Seed Raised $625K · modeled $8.3M (est)Thyron Pharmaceuticals, Inc. · Pre-Seed Raised $500K · modeled $8.2M (est)Gelesis Holdings, Inc. · Pre-Seed Raised $576K · modeled $7.9M (est)MEDPhlow, LLC · Pre-Seed Raised $1.0M · modeled $6.6M (est)Centaur Bio Inc. · Pre-Seed Raised $1.5M · modeled $5.5M (est)7 Hills Pharma Inc. · Pre-Seed Raised $1.0M · modeled $4.9M (est)Artin Bioscience Inc. · Pre-Seed Raised $483K · modeled $4.8M (est)Precision Genetics, Inc. · Pre-Seed Raised $1.0M · modeled $4.8M (est)Zena Therapeutics Inc. · Pre-Seed Raised $500K · modeled $3.8M (est)EpiVario Inc. (this company) Raised $1.1M · modeled $750K (est)EpiVario Inc.
CompanyStageRaised · realValue · estvs peer med.
Eleison Pharmaceuticals IncPre-Seed$980K$15.9M6.25×
Telomir Pharmaceuticals, Inc.Pre-Seed$1.0M$9.7M3.81×
Drusolv Therapeutics, Inc.Pre-Seed$500K$8.5M3.33×
TF Tech Ventures, Inc.Pre-Seed$625K$8.3M3.25×
Thyron Pharmaceuticals, Inc.Pre-Seed$500K$8.2M3.23×
Gelesis Holdings, Inc.Pre-Seed$576K$7.9M3.10×
MEDPhlow, LLCPre-Seed$1.0M$6.6M2.57×
Centaur Bio Inc.Pre-Seed$1.5M$5.5M2.15×
7 Hills Pharma Inc.Pre-Seed$1.0M$4.9M1.94×
Artin Bioscience Inc.Pre-Seed$483K$4.8M1.88×
Precision Genetics, Inc.Pre-Seed$1.0M$4.8M1.87×
Zena Therapeutics Inc.Pre-Seed$500K$3.8M1.50×
EpiVario Inc. this companyPre-Seed$1.1M$750K0.29×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$205K2018-09-12$1.1M$9.7M90%
Pre-Seed$540K2018-09-12$3.0M$25.5M90%
Pre-Seed$446K2018-09-12$2.5M$21.1M90%
Pre-Seed$600K2018-09-12$3.3M$28.4M90%
Pre-Seed$233K2021-07-30$1.3M$5.9M90%
Pre-Seed$135K2022-08-26$750K$1.8M90%
Pre-Seed$125K2024-01-08$694K$750K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$205K2018-09-12
    • First recorded raise — entered as Pre-Seed.
    • 8 investors on this round.
  2. Pre-Seed$540K2018-09-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.6× larger than the prior — scaling up.
    • 23 investors on this round.
  3. Pre-Seed$446K2018-09-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 22 investors on this round.
  4. Pre-Seed$600K2018-09-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× larger than the prior — scaling up.
    • 23 investors on this round.
  5. Pre-Seed$233K2021-07-30
    • Raised again after 35 mo — slower than the ~13 mo sector norm.
    • Round 2.6× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  6. Pre-Seed$135K2022-08-26
    • Raised 13 mo later, in step with the ~13 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  7. Pre-Seed$125K2024-01-08
    • Raised 16 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 3 investors on this round.
Intelligence
2024 ~Q4
Modeled next raise · ~11mo cadence
$125K
Modeled next size est.range $125K$200K
0.9×
Last step-up
$205K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Thomas Kim3 other2018-09
Michael Dishowitz1 other2018-09
Yi-Yen Chen1 other2024-01
Eric Schultenover2018-09
Philipp Mews2018-09
Registry & provenance

EpiVario Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1753351
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Fedora Pharmaceuticals Inc.PharmaceuticalsPre-Seed$1.1M$2.5Msame sector · same stage
NanoPharm LLCPharmaceuticalsPre-Seed$1.1M$14.2Msame sector · same stage
7 Hills Pharma Inc.PharmaceuticalsPre-Seed$1.0M$4.9Msame sector · same stage
ABLi Therapeutics, Inc.PharmaceuticalsPre-Seed$1.0M$2.2Msame sector · same stage
Adora Animal Health CorpPharmaceuticalsPre-Seed$1.0M$2.5Msame sector · same stage
Akanocure Pharmaceuticals, LLCPharmaceuticalsPre-Seed$1.0M$1.4Msame sector · same stage
Applied Bioresearch, Inc.PharmaceuticalsPre-Seed$1.0M$11.8Msame sector · same stage
Essentia Pharma Mountain West, LLCPharmaceuticalsPre-Seed$1.0M$1.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
EpiVax Therapeutics, Inc.BiotechnologySeed$14.8M83%
Vivera Pharmaceuticals, Inc.PharmaceuticalsSeed$40.1M82%
Enumeral Biomedical Holdings, Inc.PharmaceuticalsSeries B$22.7M81%
Oligomerix, Inc.PharmaceuticalsSeed$37.8M81%
Gelesis Holdings, Inc.PharmaceuticalsPre-Seed$7.9M81%
PharmaCielo Ltd.PharmaceuticalsSeries A$195.6M81%
MedAvail Holdings, Inc.PharmaceuticalsSeries B$679.3M81%
Eletala Enterprises IncPharmaceuticalsPre-Seed$185K80%
Frequently asked
How much funding has EpiVario Inc. raised?
EpiVario Inc. has raised approximately $1.1M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is EpiVario Inc.'s estimated valuation?
Provath's modeled valuation for EpiVario Inc. is approximately $750K (modeled range $70K–$2.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is EpiVario Inc. at?
EpiVario Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Mon Jan 08.
What does EpiVario Inc. do and where is it based?
EpiVario Inc. operates in the Pharmaceuticals sector, based in PHILADELPHIA.
Explore related

See where EpiVario Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at EpiVario Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.